Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 16/20 | 1.00 |
| ▸ | PDK2 | Q15119 | 16/20 | 1.00 |
| ▸ | PDK3 | Q15120 | 16/20 | 1.00 |
| ▸ | PDK4 | Q16654 | 16/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.60 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549170 | 1.00 | PDK1 (1.00) | PDK1PDK2PDK3PDK4ABCB11 | |
| SCHEMBL6350254 | 1.00 | PDK1 (1.00) | PDK1PDK2PDK3PDK4ABCB11 | |
| SCHEMBL30709628 | 1.00 | PDK1 (1.00) | PDK1PDK2PDK3PDK4ABCB11 | |
| SCHEMBL6568368 | 0.91 | PDK1 (0.83) | PDK1PDK2PDK3PDK4ABCB11 | |
| SCHEMBL6570111 | 0.89 | PDK1 (0.80) | PDK1PDK2PDK3PDK4ABCB11 | |
| SCHEMBL6570108 | 0.89 | PDK1 (0.80) | PDK1PDK2PDK3PDK4ABCB11 | |
| SCHEMBL6568122 | 0.88 | PDK1 (0.78) | PDK1PDK2PDK3PDK4ABCB11 | |
| SCHEMBL6348880 | 0.88 | PDK1 (0.78) | PDK1PDK2PDK3PDK4ABCB11 | |
| SCHEMBL6348885 | 0.88 | PDK1 (0.78) | PDK1PDK2PDK3PDK4ABCB11 | |
| SCHEMBL6568114 | 0.88 | PDK1 (0.78) | PDK1PDK2PDK3PDK4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208478-B2 | Methods of detecting and treating a tumor expressing pT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-12-28 | — | — | US | claimed |
| US-20190177411-A1 | Methods of Detecting and Treating a Tumor Expressing PT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-06-13 | — | — | US | claimed |
| EP-3493818-A1 | METHODS OF DETECTING AND TREATING A TUMOR EXPRESSING PT346 PDK1 | The Wistar Institute Of Anatomy And Biology (US) | 2019-06-12 | — | — | EP | claimed |
| WO-2018031407-A1 | METHODS OF DETECTING AND TREATING A TUMOR EXPRESSING PT346 PDK1 | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2018-02-15 | — | — | WO | claimed |
| US-20180028647-A1 | MODIFICATIONS OF THERAPEUTIC AGENTS FOR ENHANCED DELIVERY TO TARGET SITES | CLARIA ODIN LLC | 2018-02-01 | — | — | US | claimed |
| WO-2013109142-A1 | COMBINED PDK AND MAPK/ERK PATHWAY INHIBITION IN NEOPLASIA | STICHTING HET NEDERLANDS KANKER INSTITUUT (NL) | 2013-07-25 | — | — | WO | claimed |
| EP-1082110-B1 | USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 2004-03-24 | — | — | EP | claimed |
| US-20040009979-A1 | Use of compounds for the elevation of pyruvate dehydrogenase activity | ZENECA LIMITED | 2004-01-15 | — | — | US | claimed |
| US-6498275-B1 | Use of compounds for the elevation of pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2002-12-24 | — | — | US | claimed |
| EP-1082110-A1 | USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY | AstraZeneca AB (SE) | 2001-03-14 | — | — | EP | claimed |
| WO-1999062506-A1 | USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250367157-A1 | COMPOSITION FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DYSFUNCTION OF MITOCHONDRIAE | IUF LEIBNIZ INST FUER UMWELTMEDIZINISCHE FORSCHUNG GMBH (DE) | 2025-12-04 | — | — | US | disclosed |
| US-12377063-B2 | Combination therapies for managing cancer | EMORY UNIVERSITY (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4578440-A1 | NON-THERAPEUTIC METHODS FOR SKIN TANNING | IUF Leibnitz-Institut für umweltmedizinische Forschung GmbH (DE) | 2025-07-02 | — | — | EP | disclosed |
| US-20180028647-A1 | MODIFICATIONS OF THERAPEUTIC AGENTS FOR ENHANCED DELIVERY TO TARGET SITES | CLARIA ODIN LLC | 2018-02-01 | — | — | US | disclosed |
| WO-2013109142-A1 | COMBINED PDK AND MAPK/ERK PATHWAY INHIBITION IN NEOPLASIA | STICHTING HET NEDERLANDS KANKER INSTITUUT (NL) | 2013-07-25 | — | — | WO | disclosed |
| US-6960688-B2 | Use of compounds for the elevation of pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2005-11-01 | — | — | US | disclosed |
| US-20040009979-A1 | Use of compounds for the elevation of pyruvate dehydrogenase activity | ZENECA LIMITED | 2004-01-15 | — | — | US | disclosed |
| US-6498275-B1 | Use of compounds for the elevation of pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2002-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009979-A1 | Use of compounds for the elevation of pyruvate dehydrogenase activity | PDHA1, PDK1, PDHB | PDK1 2/4885PDK2 8/4885PDK3 7/4885 |
| US-20180028647-A1 | MODIFICATIONS OF THERAPEUTIC AGENTS FOR ENHANCED DELIVERY TO TARGET SITES | PDK1, PC, PDK2 | PDK1 1/4885PDK2 3/4885PDK3 16/4885 |
| US-11208478-B2 | Methods of detecting and treating a tumor expressing pT346 PDK1 | PDK1, PDK2, PCK2 | PDK1 1/4885PDK2 2/4885PDK3 4/4885 |
| US-12377063-B2 | Combination therapies for managing cancer | PCK2, PDK1, PC | PDK1 2/4885PDK2 4/4885PDK3 8/4885 |
| US-20190177411-A1 | Methods of Detecting and Treating a Tumor Expressing PT346 PDK1 | PDK1, PDK2, PCK2 | PDK1 1/4885PDK2 2/4885PDK3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.